• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Talquetamab Plus Teclistamab Shows Promise in Multiple Myeloma

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 10, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, Jan. 9, 2025 -- For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or 4 infections than with either therapy alone, according to a study published in the Jan. 9 issue of the New England Journal of Medicine.

Yael C. Cohen, M.D., from the Tel Aviv Sourasky Medical Center in Israel, and colleagues conducted a phase 1b-2 study of talquetamab plus teclistamab in patients with relapsed or refractory multiple myeloma. Five dose levels were investigated in a dose-escalation study in phase 1. The recommended phase 2 regimen was talquetamab at a dose of 0.8 mg/kg body weight plus teclistamab at a dose of 3.0 mg/kg every other week. The primary objective of the study was to evaluate adverse events and dose-limiting toxic effects.

Ninety-four patients received treatment; 44 used the recommended phase 2 regimen. Patients were followed for a median of 20.3 months. The researchers found that three patients had dose-limiting toxic effects (including one with grade 4 thrombocytopenia, who received the recommended phase 2 regimen). The most common adverse events across all dose levels were cytokine release syndrome, neutropenia, taste changes, and nonrash skin events. Ninety-six percent of patients had grade 3 or 4 adverse events, most often hematologic events. Sixty-four percent of patients had grade 3 or 4 infections. A response occurred in 80 percent of the patients with the recommended phase 2 regimen and in 78 percent across all dose levels. The likelihood of patients continuing in response at 18 months was 86 and 77 percent with the recommended phase 2 regimen and across all dose levels, respectively.

"On the basis of these results, this dual-targeting, off-the-shelf combination therapy warrants further investigation in patients with relapsed or refractory multiple myeloma," the authors write.

The study was funded by Janssen, which manufactures talquetamab and teclistamab.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted January 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.